Exousia Pro, Inc. Receives Comments from FINRA Regarding Name Change
Orlando, Florida – April 3, 2025 – Exousia Pro, Inc. (OTC PINK: MAJI), a clinical-stage biotech company specializing in the application of exosomes in cancer and other disease treatments, has recently received comments from the Financial Industry Regulatory Authority (FINRA) regarding the company’s proposed name change.
Background
Exousia Pro, Inc. has been making headlines in the biotech industry with its innovative approach to treating various diseases using exosomes. Exosomes are tiny vesicles that naturally occur in the body and can carry therapeutic agents to target cells. The company’s focus on this technology has shown promising results in preclinical studies for cancer, Alzheimer’s disease, and other conditions.
Name Change Announcement
On March 15, 2025, Exousia Pro, Inc. announced its intention to change its name to Marijuana Inc. This decision was made to better reflect the company’s potential expansion into the cannabis industry. The company plans to develop and market cannabinoid-based therapies using its exosome technology.
FINRA Comments
FINRA’s comments, received on March 29, 2025, requested additional information from the company regarding the proposed name change. Specifically, FINRA requested clarification on how the new name would align with the company’s business activities and whether there would be any potential regulatory issues.
Impact on Shareholders
For shareholders, the name change could potentially bring both opportunities and challenges. On the one hand, the new name could attract investors interested in the cannabis industry, leading to increased market visibility and potential growth. On the other hand, there may be regulatory hurdles to overcome, which could impact the company’s timeline for bringing new products to market.
Impact on the World
From a global perspective, Exousia Pro’s proposed entry into the cannabis industry using exosome technology could have significant implications. The use of exosomes in cannabinoid-based therapies could lead to more targeted and effective treatments for various conditions, including pain management, neurodegenerative diseases, and cancer. However, this new application of the technology may also face regulatory challenges, especially in countries where cannabis use is still heavily restricted.
Conclusion
Exousia Pro, Inc.’s proposed name change to Marijuana Inc. and its entry into the cannabis industry using exosome technology represents an exciting development in the biotech sector. While the company faces regulatory hurdles, the potential benefits of this innovative approach to cannabinoid-based therapies could lead to significant advancements in the treatment of various conditions. Shareholders and the global community will be watching closely as Exousia Pro navigates this new chapter in its journey.
- Exousia Pro, Inc. is a clinical-stage biotech company specializing in exosome technology for disease treatments
- The company announced its intention to change its name to Marijuana Inc. to better reflect its potential expansion into the cannabis industry
- FINRA has requested additional information regarding the proposed name change and alignment with business activities
- The name change could bring opportunities and challenges for shareholders, including increased visibility and potential regulatory hurdles
- Exousia Pro’s entry into the cannabis industry using exosome technology could lead to significant advancements in treatment for various conditions
